1. Home
  2. KPTI vs MCHX Comparison

KPTI vs MCHX Comparison

Compare KPTI & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • MCHX
  • Stock Information
  • Founded
  • KPTI 2008
  • MCHX 2003
  • Country
  • KPTI United States
  • MCHX United States
  • Employees
  • KPTI N/A
  • MCHX N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • KPTI Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • KPTI Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • KPTI 81.1M
  • MCHX 84.3M
  • IPO Year
  • KPTI 2013
  • MCHX 2004
  • Fundamental
  • Price
  • KPTI $0.62
  • MCHX $1.95
  • Analyst Decision
  • KPTI Strong Buy
  • MCHX
  • Analyst Count
  • KPTI 4
  • MCHX 0
  • Target Price
  • KPTI $5.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • KPTI 679.6K
  • MCHX 26.5K
  • Earning Date
  • KPTI 02-27-2025
  • MCHX 03-13-2025
  • Dividend Yield
  • KPTI N/A
  • MCHX N/A
  • EPS Growth
  • KPTI N/A
  • MCHX N/A
  • EPS
  • KPTI N/A
  • MCHX N/A
  • Revenue
  • KPTI $148,442,000.00
  • MCHX $48,594,000.00
  • Revenue This Year
  • KPTI $5.47
  • MCHX N/A
  • Revenue Next Year
  • KPTI $6.33
  • MCHX $4.63
  • P/E Ratio
  • KPTI N/A
  • MCHX N/A
  • Revenue Growth
  • KPTI 1.77
  • MCHX N/A
  • 52 Week Low
  • KPTI $0.58
  • MCHX $1.11
  • 52 Week High
  • KPTI $1.70
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 41.95
  • MCHX 48.44
  • Support Level
  • KPTI $0.60
  • MCHX $1.88
  • Resistance Level
  • KPTI $0.69
  • MCHX $2.06
  • Average True Range (ATR)
  • KPTI 0.05
  • MCHX 0.09
  • MACD
  • KPTI -0.00
  • MCHX -0.00
  • Stochastic Oscillator
  • KPTI 18.17
  • MCHX 60.71

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: